By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Abbott today said that it has completed submissions in the US and Japan for a molecular diagnostic test to detect abnormal gene rearrangements in non-small cell lung cancer tumors.

The test uses fluorescence in situ hybridization technology and has been developed to detect rearrangements in the 2p23 chromosome of the ALK gene. Abbott said that these abnormalities have been implicated in the development of NSCLC, lymphoma, and neuroblastoma.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: co-evolutionary signatures of insect hosts and bacterial symbionts, distinct transcript isoforms of high-grade ovarian cancer, and more.

Adam Rutherford discusses genetic genealogy at the Guardian.

Portions of the US 21st Century Cures Act are raising some safety concerns.

David Dobbs writes at Buzzfeed that genomics has delivered little on its promises.